Neurocrine presents new INGREZZA capsules data

Neurocrine Biosciences announced new data on now FDA-approved INGREZZA capsules for the treatment of adults with chorea associated with Huntington’s disease, HD, including exploratory results from the Phase 3 KINECT-HD study, which showed consistently greater improvements in HD chorea with INGREZZA versus placebo from Week 2 to Week 12. These data will be presented at the MDS International Congress of Parkinson’s Disease and Movement Disorders August 27-31 in Copenhagen, Denmark. “The exploratory analysis from our KINECT-HD study further exemplifies the value of INGREZZA as a now approved medication for HD chorea with improvements seen with treatment as early as two weeks,” said Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. “Additional analyses presented add to the body of evidence regarding the use of INGREZZA for this patient population, including an increased understanding of Unified Huntington’s Disease Rating Scale Total Maximal Chorea scores that signal clinically meaningful chorea improvements.” KINECT-HD, a Phase 3, randomized, double-blind, placebo-controlled study met its primary endpoint of chorea reduction as assessed using the UHDRS TMC score with a placebo-adjusted improvement of 3.2 points at Week 12 among those receiving INGREZZA. Secondary endpoints also demonstrated significantly greater improvements at Week 12 among those treated with INGREZZA compared with placebo as assessed using the Clinical Global Impression of Change and Patient Global Impression of Change. These findings were recently published in The Lancet Neurology.